These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

911 related items for PubMed ID: 30383140

  • 1. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP.
    JAMA Oncol; 2018 Dec 01; 4(12):e184060. PubMed ID: 30383140
    [Abstract] [Full Text] [Related]

  • 2. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.
    JAMA; 2012 Mar 28; 307(12):1265-72. PubMed ID: 22453568
    [Abstract] [Full Text] [Related]

  • 3. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
    Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, Cameron S, Hohenberger P, Jost PJ, Al-Batran SE, Lindner LH, Bauer S, Wardelmann E, Nilsson B, Kallio R, Jaakkola P, Junnila J, Alvegård T, Reichardt P.
    JAMA Oncol; 2020 Aug 01; 6(8):1241-1246. PubMed ID: 32469385
    [Abstract] [Full Text] [Related]

  • 4. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.
    JAMA Oncol; 2017 May 01; 3(5):602-609. PubMed ID: 28334365
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
    Joensuu H.
    Drugs; 2012 Oct 22; 72(15):1953-63. PubMed ID: 22994537
    [Abstract] [Full Text] [Related]

  • 6. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK.
    J Manag Care Pharm; 2010 Sep 22; 16(7):482-91. PubMed ID: 20726677
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
    Sutton TL, Billingsley KG, Johnson AJ, Corless CL, Blanke CD, Heinrich MC, Mayo SC.
    J Surg Oncol; 2024 Jul 22; 130(1):40-46. PubMed ID: 38924626
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
    Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P.
    J Clin Oncol; 2016 Jan 20; 34(3):244-50. PubMed ID: 26527782
    [Abstract] [Full Text] [Related]

  • 9. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
    Gronchi A, Bonvalot S, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom HJ, van Coevorden F, Penel N, Kopp HG, Duffaud F, Goldstein D, Broto JM, Wardelmann E, Marréaud S, Smithers M, Le Cesne A, Zaffaroni F, Litière S, Blay JY, Casali PG.
    JAMA Surg; 2020 Jun 01; 155(6):e200397. PubMed ID: 32236507
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z, Gao J, Gong J, Li J, Li Y, Wang X, Li Y, Shen L, Li J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov 25; 19(11):1286-1289. PubMed ID: 27928801
    [Abstract] [Full Text] [Related]

  • 11. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
    Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.
    JAMA Oncol; 2017 Jul 01; 3(7):944-952. PubMed ID: 28196207
    [Abstract] [Full Text] [Related]

  • 12. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
    Wu X, Li J, Xu W, Gao J, Li Y, Shen L.
    Future Oncol; 2018 Jul 01; 14(17):1721-1729. PubMed ID: 29969914
    [Abstract] [Full Text] [Related]

  • 13. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
    Guérin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP.
    JAMA Oncol; 2015 Sep 01; 1(6):797-805. PubMed ID: 26204106
    [Abstract] [Full Text] [Related]

  • 14. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.
    Ann Surg; 2013 Sep 01; 258(3):422-9. PubMed ID: 23860199
    [Abstract] [Full Text] [Related]

  • 15. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y, Hao H, Guo L, Yang G, Zhang X.
    Oncotarget; 2017 Feb 07; 8(6):10136-10144. PubMed ID: 28052037
    [Abstract] [Full Text] [Related]

  • 16. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P, Ziętek M, Cybulska-Stopa B, Streb J, Głuszek S, Jankowski M, Łopacka-Szatan K, Las-Jankowska M, Hudziec P, Klimczak A, Olesiński T, Świtaj T, Koseła-Paterczyk H, Bylina E, Osuch C.
    Eur J Surg Oncol; 2021 May 07; 47(5):1191-1195. PubMed ID: 32826113
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J, Dang YZ, Gao J, Shen L.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar 07; 16(3):216-20. PubMed ID: 23536338
    [Abstract] [Full Text] [Related]

  • 18. Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
    Reichardt P, Schlemmer M, Delgado Perez JR, Papai Z, Prausova J, Melichar B, Fumagalli E, Barone C, Bauer S, Pustowka A, Crippa S, Castellana R, Quiering C, Le Cesne A.
    Oncol Res Treat; 2019 Mar 07; 42(12):629-635. PubMed ID: 31550719
    [Abstract] [Full Text] [Related]

  • 19. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    Cancer Chemother Pharmacol; 2013 Jan 07; 71(1):43-51. PubMed ID: 23053257
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.